Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Patents Face 'Real Threat' From Inter Partes Review; PTAB Open To Change

Executive Summary

Pfizer attorney says brand-name drug companies no longer can rely on the outcome of ANDA litigation to predict date of generic competition; PTAB chief judge observes that there is 'opportunity to get some more certainty for patent owners.'


Related Content

Pfizer Keeps IPR Winning Streak; Court Affirms Ruling On Tygacil Patent
Supreme Court Upholds IPR Standard Making Patent Invalidation Easier; Will Congress Reverse?


Related Companies